Spondyloarthritis & psoriatic arthritis
Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics?
Study context
- Population
- Patients with moderate-to-severe plaque psoriasis (PsO) and mild psoriatic arthritis (PsA)
- Comparison
- IL-17 inhibitors vs IL-23 inhibitors for moderate-to-severe PsO with mild PsA
Methodological detailsDebate at the 2022 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) conference
- Debate at the 2022 GRAPPA conference
Main finding
As reported in the abstract
- No head-to-head studies; unclear which agent is better suited for moderate-to-severe PsO with mild PsA
Original publication
Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics? J Rheumatol. Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →